Spectrum Pharmaceuticals, Inc. has received from the US Patent and Trademark Office (USPTO) a Notice of Allowance for its patent application for SPI-339 entitled "Methods for Treating Cognitive/Attention Deficit Disorders Using Tetrahydroindolone Analogues and Derivatives." This patent, when issued, will protect SPI-339 for use in the treatment of ADHD and other neurological disorders and will not expire until 2021.

"We are happy to receive this notice of allowance on SPI-339," Rajesh C. Shrotriya, chairman, CEO and president of Spectrum Pharmaceuticals, Inc. said adding, "This patent, when issued, will be a significant addition to our intellectual property portfolio on our Central Nervous System (CNS) compounds and will strengthen our ability to out-license this product for further development and marketing by a partner. In addition to SPI-339, our CNS portfolio includes antipsychotic compounds SPI-376 and SPI-392, all of which are available out-licensing opportunities."

SPI-339 is an orally available small molecule drug that has potential applications for the treatment of attention disorders, memory acquisition and other cognitive functions. Potential applications of SPI-339 include treatment of children and adults with Attention Deficit and Hyperactivity Disorder (ADHD). Although the precise mechanism of action of SPI-339 is not known, it is known to be different from that of the stimulants that are commonly used to treat ADHD.